Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021
Yahoo! Finance
ANG-3070 was well-tolerated across dose cohorts, achieving drug exposures in humans exceeding exposures in which activity was demonstrated in animal models of proteinuric kidney diseasesPharmacokinetic data potentially supportive of once-daily dosingAn international Phase 2 trial in patients with primary proteinuric kidney diseases will begin enrolling patients in the second half of this yearCompany to host a Virtual Fibrosis R&D Day on September 20, 2021 UNIONDALE, N.Y., Aug. 03, 2021 (GLOBE NE
Continue Reading